Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianzhao Zhang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Jingwei Tian

    School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China

    5 shared publications
  • Jing Lu

    School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China; State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong, 264003, China

    4 shared publications
  • Wenyan Wang

    School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China; State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong, 264003, China

    4 shared publications
  • Chunjiao Liu

    State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong, 264003, China

    3 shared publications
  • Hongbo Wang

    Space Information Research Institute and Zhejiang Key Laboratory of Space Information Sensing and Transmission, Hangzhou Dianzi University, Hangzhou, China

    3 shared publications
  • Yifei Yang

    School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China

    3 shared publications

Latest Publications

  • Open Access

    Cuproptosis in Ischemic Stroke: Molecular Mechanisms and Therapeutic Potential

    by Xinyu Han, Wenjing Zhang, Huanhuan An, Jianzhao Zhang, Jingwei Tian, Yunjie Wang

    Stroke is a major neurological disease caused by cerebral vascular obstruction or rupture and represents a leading cause of death and long-term disability worldwide. Ischemic stroke (IS) accounts for the majority of stroke cases, while effective therapeutic strategies remain limited. Therefore, a better understanding of the underlying pathological mechanisms and the identification of new therapeutic targets are urgently needed. Cerebral ischemia triggers various regulated forms of cell death, including apoptosis, ferroptosis, and cuproptosis, which was discovered in recent years. Emerging evidence suggests that copper imbalance and copper-dependent cell death may play important roles in the development and progression of IS. This review summarizes the molecular mechanisms of cuproptosis and its potential involvement in cerebral ischemia, and discusses the therapeutic potential of cuproptosis-targeting agents for improving neurological outcomes after stroke.

  • Targeting RIPK1-mediated necroptosis, oxidative stress, and ferroptosis: A novel multitarget therapy for ischemic stroke

    by Ziwei Song, Liang Ye, Yunjie Wang, Wenyan Wang, Chunjiao Liu, Jing Lu, Jiajing Zhang, Hongbo Wang, Jianzhao Zhang, Yifei Yang, et al.


  • Open Access

    Ferroptosis in Ischemic Stroke and Related Traditional Chinese Medicines

    by Runchen Ma, Xiaohui Sun, Zhaofeng Liu, Jianzhao Zhang, Gangqiang Yang, Jingwei Tian, Yunjie Wang

    Stroke is a severe neurological disorder resulting from the rupture or blockage of blood vessels, leading to significant mortality and disability worldwide. Among the different types of stroke, ischemic stroke (IS) is the most prevalent, accounting for 70–80% of cases. Cell death following IS occurs through various mechanisms, including apoptosis, necrosis, and ferroptosis. Ferroptosis, a recently identified form of regulated cell death characterized by iron overload and lipid peroxidation, was first described by Dixon in 2012. Currently, the only approved pharmacological treatment for IS is recombinant tissue plasminogen activator (rt-PA), which is limited by a narrow therapeutic window and often results in suboptimal outcomes. Recent research has identified several traditional Chinese medicines (TCMs) that can inhibit ferroptosis, thereby mitigating the damage caused by IS. This review provides an overview of stroke, the role of ferroptosis in IS, and the potential of certain TCMs to inhibit ferroptosis and contribute to stroke treatment.


  • Open Access

    Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

    by Zhaofeng Liu, Yifei Yang, Xiaohui Sun, Runchen Ma, Wenjing Zhang, Wenyan Wang, Gangqiang Yang, Hongbo Wang, Jianzhao Zhang, Yunjie Wang, et al.

    Cell cycle-dependent kinase 2 (CDK2) is located downstream of CDK4/6 in the cell cycle and regulates cell entry into S-phase by binding to Cyclin E and hyper-phosphorylating Rb. Proto-oncogene murine double minute 2 (MDM2) is a key negative regulator of p53, which is highly expressed in tumors and plays an important role in tumorigenesis and progression. In this study, we identified a dual inhibitor of CDK2 and MDM2, III-13, which had good selectivity for inhibiting CDK2 activity and significantly reduced MDM2 expression. In vitro results showed that III-13 inhibited proliferation of a wide range of tumor cells, regardless of whether Cyclin E1 (CCNE1) was overexpressed or not. The results of in vivo experiments showed that III-13 significantly inhibited proliferation of tumor cells and did not affect body weight of mice. The results of the druggability evaluation showed that III-13 was characterized by low bioavailability and poor membrane permeability when orally administered, suggesting the necessity of further structural modifications. Therefore, this study provided a lead compound for antitumor drugs, especially those against CCNE1-amplified tumor proliferation.


  • Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1

    by Jing Lu, Hui Lei, Xinfa Bai, Wenyan Wang, Chunjiao Liu, Yifei Yang, Fangxia Zou, Lin Wang, Yunjie Wang, Guangying Du, et al.


  • Open Access

    Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment

    by Yunjie Wang, Zhaofeng Liu, Jing Lu, Wenyan Wang, Lin Wang, Yifei Yang, Hongbo Wang, Liang Ye, Jianzhao Zhang, Jingwei Tian

    Introduction: Schizophrenia is a serious mental illness that requires effective treatment with minimal adverse effects. As preclinical and clinical research progresses, trace amine-associated receptor 1 (TAAR1) is becoming a potential new target for the treatment of schizophrenia.Methods: We used molecular docking and molecular dynamics (MD) simulations to discover TAAR1 agonists. The agonistic or inhibitory effects of compounds on TAAR1, 5-HT1A, 5-HT2A, and dopamine D2-like receptors were determined. We used an MK801-induced schizophrenia-like behavior model to assess the potential antipsychotic effects of compounds. We also performed a catalepsy assay to detect the adverse effects. To evaluate the druggability of the compounds, we conducted evaluations of permeability and transporter substrates, liver microsomal stability in vitro, human ether-à-go-go-related gene (hERG), pharmacokinetics, and tissue distribution.Results: We discovered two TAAR1 agonists: compounds 50A and 50B. The latter had high TAAR1 agonistic activity but no agonistic effect on dopamine D2-like receptors and demonstrated superior inhibition of MK801-induced schizophrenia-like behavior in mice. Interestingly, 50B had favorable druggability and the ability to penetrate the blood-brain barrier (BBB) without causing extrapyramidal symptoms (EPS), such as catalepsy in mice.Conclusion: These results demonstrate the potential beneficial role of TAAR1 agonists in the treatment of schizophrenia. The discovery of a structurally novel TAAR1 agonist (50B) may provide valuable assistance in the development of new treatments for schizophrenia.


  • Open Access

    Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS

    by Lin Wang, Hui Lei, Jing Lu, Wenyan Wang, Chunjiao Liu, Yunjie Wang, Yifei Yang, Jingwei Tian, Jianzhao Zhang

    PLK-1 (Polo-like kinase-1) plays an essential role in cytokinesis, and its aberrant expression is considered to be keenly associated with a wide range of cancers. It has been selected as an appealing target and small-molecule inhibitors have been developed and studied in clinical trials. Unfortunately, most have been declared as failures due to the poor therapeutic response and off-target toxicity. In the present study, a novel potent PLK-1 inhibitor, compound 7a, was designed and synthetized. 1H NMR, 13C NMR, 19F NMR and mass spectrum were comprehensively used for the compound characterization. The compound exhibited higher potency against PLK-1 kinase, HCT-116 and NCI-H2030 cell lines than the positive control. Molecular docking indicated that the binding mode that the ATP binding site of PLK-1 was occupied by the compound. Then, a UHPLC-MS/MS method was established and validated to explore the pharmacokinetic behavior of the drug candidate. The method had good selectivity, high sensitivity and wide linearity. The exposure increased linearly with the dose, but the oral bioavailability was not satisfactory enough. Then, the metabolism was studied using liver microsomes by UHPLC-Q-Orbitrap/HRMS. Our research first studied the pharmacokinetic metabolic characteristics of 7a and may serve as a novel lead compound for the development of PLK-1 inhibitors.


  • Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist

    by Fangxia Zou, Yao Wang, Dawei Yu, Chunjiao Liu, Jing Lu, Min Zhao, Mingxu Ma, Wenyan Wang, Wanglin Jiang, Yonglin Gao, et al.


  • Open Access

    FNDC3B is associated with ER stress and poor prognosis in cervical cancer

    by Bing Han, Hongbo Wang, Jianzhao Zhang, Jingwei Tian

    Currently, the occurrence and mortality rate of cervical cancer is high, particularly in low‑to‑middle‑income countries. Therefore, the development of novel diagnostic and treatment strategies for cervical cancer is urgently required. The aim of the present study was to assess the prognostic significance of fibronectin type III domain containing 3B (FNDC3B) expression in patients with cervical cancer and to determine the underlying mechanism of FNDC3 in tumor development. Analysis of the ONCOMINE database revealed that FNDC3B was significantly upregulated in cervical cancer tissue compared with normal tissue. Additionally, FNDC3B expression data and the clinical characteristics of patients with cervical cancer were obtained from the cBioPortal database. Correlations between FNDC3B expression and overall survival were subsequently investigated. The results revealed that increased FNDC3B expression was significantly correlated with a lower overall survival in patients with cervical cancer. A co‑expression network was subsequently constructed to elucidate the function of FNDC3B in cervical cancer. Co‑expression genes for FNDC3B were obtained from the cBioPortal database and were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. The results demonstrated that the genes were enriched in pathways associated with migration, invasion, endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). Furthermore, immunofluorescence results obtained from the Human Protein Atlas revealed that the FNDC3B protein was localized to the ER. The results revealed that upregulated FNDC3B expression may be a biomarker for poor prognosis for patients with cervical cancer. Additionally, the results revealed that FNDC3B may serve an oncogenic role in cancer development via ER stress, UPR, cell migration and invasion. However, further studies are required to determine the exact molecular mechanism of FNDC3B in the development of cervical cancer and to assess its potential as a novel therapeutic target for the treatment of this disease.